Discovery OverviewThe CombinatoRx combination High Throughput Screening technology, cHTS™, is a robotic screening system, including both customized hardware and software elements, that screens dose-specific combinations including, but not limited to, the pharmacopeia of approved drugs in cell-based assays for the diseases we are targeting. This approach transcends the separate mechanisms of the individual drug components, because CombinatoRx's product candidates treat diseases through entirely new mechanisms of action enabled by the synergies of these combinations. Renewable and Untapped Source of DrugsThe CombinatoRx drug discovery engine, fueled by the vast number of possible combinations, can test millions of drug combinations to discover new mechanisms to treat diseases. Potential pharmaceuticals can then be screened against proven models of a disease, including both known and novel disease targets, to generate large numbers of potential drug leads. Synergistic Combinations - Potentially Safer and More Active PharmaceuticalsBy targeting multiple physiologic pathways and hitting multiple targets within the body, CombinatoRx's technological platform creates product candidates with novel mechanisms which may better treat a wide variety of serious diseases with:
CombinatoRx uses these advantages to strengthen its own drug development efforts as well as to generate valuable collaborative relationships. Our Focus: Discovery, Development of Novel Synergistic CombinationsCombinatoRx is focused on discovery and developing novel synergistic combination therapeutics to treat a number of conditions including immuno-inflammatory diseases, cancer, pain, metabolic diseases, neurodegenerative diseases, infectious diseases and other diseases. Key elements of our strategy are:
|
|
|
 |
